Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 9 June 2021, 12:44 HKT/SGT
Share:
    

Source: Eisai
Eisai Receives Special Prize at Platinum Career Award 2021

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received a special prize at the Platinum Career Award 2021. The awards ceremony was held via online at the symposium on June 8, 2021.

The Platinum Career Award was established in 2019 with the aim of commending companies that aspire to provide opportunities for employees to develop their career and play an active role, in order to realize career paths that Japanese employees are aiming for in the era of the 100 years' life. (This event was held with sponsorship and planning by Mitsubishi Research Institute, Inc., planning by Mitsubishi UFJ Trust and Banking Corporation, support by the Ministry of Health, Labour and Welfare, Japan, and Tokyo Stock Exchange, Inc., and cooperation from TOYO KEIZAI INC.). Eisai received a special prize dedicated to companies that are implementing "new working styles initiated to adjust with the era of Corona (COVID-19 Pandemic)".

Eisai defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," in the articles of incorporation, which we call our human health care (hhc) philosophy.

Eisai will enhance the development of self-reliant talents, so that each and every employee who sympathize with its corporate philosophy can adapt themselves to any changes and contribute to the creation of new social value through working independently with high motivation. By promoting work and learning style reforms to achieve this goal, Eisai attempts to transition from a company-led career development style to a proactive career development style based on the diversity of values of individual employees and their willingness to take on challenges. In addition, Eisai will work on expanding the range of individual discretion in choosing work locations and working hours, as well as implementing new measures for utilizing IT tools in terms of both hardware and software, such as efficiently providing training opportunities for all employees to independently learn new skills and acquire new working experiences, adopting a special paid leave system that can be used for self-development and social contribution activities, and promoting online dialogue between members inside and outside the organization.
Eisai will make continuous efforts based on the hhc philosophy to further contribute to increasing the benefits of patients and their families around the world.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: